A novel therapeutic approach to correct CKD-associated anemia is the induction of EPO synthesis by stabilizing hypoxia-inducible factors (HIFs) with prolyl hydroxylase inhibitors (PHIs). The gene discussed is EPO; the disease is chronic kidney disease.